Phathom Pharmaceuticals (PHAT) EBT Margin (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has reported EBT Margin for 4 consecutive years, with 37.69% the latest figure, recorded in Q2 2026.

• In Q2 2026, EBT Margin rose 17347.0% year-over-year to 37.69%; the TTM figure through Jun 2026 stood at 63.56% (up 21371.0% YoY), while the FY2025 annual figure was 261.87%, up 67502.0% from the prior year.
• EBT Margin climbed to 37.69% in Q2 2026 per PHAT's latest filing, from 82.28% in the prior quarter.
• Across five years, EBT Margin topped out at 36.72% in Q4 2025 and bottomed at 14060.85% in Q4 2023.
• Historically, EBT Margin has averaged 1931.17% across 4 years, with a median of 211.16% in 2025.
• Annual changes were most pronounced in 2024 — EBT Margin surged 1399416 bps — and 2025, when it jumped 2998 bps.
• Phathom Pharmaceuticals' EBT Margin stood at 14060.85% in 2023, then surged by 100 bps to 66.69% in 2024, then soared by 45 bps to 36.72% in 2025, then retreated by 3 bps to 37.69% in 2026.
• Business Quant data shows PHAT's EBT Margin at 37.69% in Q2 2026, 82.28% in Q1 2026, and 36.72% in Q4 2025.